Form F-3 - Registration statement by foreign private issuers:
SEC Accession No. 0001213900-25-103109
Filing Date
2025-10-28
Accepted
2025-10-28 16:26:13
Documents
19

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ea0262630-f3_neurosense.htm F-3 435444
2 OPINION OF GOLDFARB GROSS SELIGMAN & CO., ISRAELI COUNSEL TO THE REGISTRANT ea026263001ex5-1_neurosense.htm EX-5.1 7558
3 CONSENT OF SOMEKH CHAIKIN (MEMBER FIRM OF KPMG INTERNATIONAL), INDEPENDENT REGIS ea026263001ex23-1_neurosense.htm EX-23.1 3313
4 FILING FEE TABLE ea026263001ex-fee_neurosense.htm   iXBRL EX-FILING FEES 13870
5 GRAPHIC image_001.jpg GRAPHIC 38219
6 GRAPHIC image_002.jpg GRAPHIC 64900
7 GRAPHIC image_003.jpg GRAPHIC 38219
8 GRAPHIC ex5-1_001.jpg GRAPHIC 11693
9 GRAPHIC ex5-1_002.jpg GRAPHIC 42000
  Complete submission text file 0001213900-25-103109.txt   851798

Data Files

Seq Description Document Type Size
21 EXTRACTED XBRL INSTANCE DOCUMENT ea026263001ex-fee_neurosense_htm.xml XML 5059
Mailing Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562
Business Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562 972-9-9531142
NeuroSense Therapeutics Ltd. (Filer) CIK: 0001875091 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: F-3 | Act: 33 | File No.: 333-291122 | Film No.: 251425176
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)